Sagittarius Life Science Corp reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 134.51 million compared to TWD 153.73 million a year ago. Net loss was TWD 23.85 million compared to TWD 18.34 million a year ago. Basic loss per share from continuing operations was TWD 0.73 compared to TWD 0.56 a year ago. Diluted loss per share from continuing operations was TWD 0.73 compared to TWD 0.56 a year ago.
For the six months, sales was TWD 268.86 million compared to TWD 301.2 million a year ago. Net loss was TWD 45.16 million compared to TWD 40.47 million a year ago. Basic loss per share from continuing operations was TWD 1.39 compared to TWD 1.24 a year ago. Diluted loss per share from continuing operations was TWD 1.39 compared to TWD 1.24 a year ago.